Hepatitis Monthly

Published by: Kowsar

Granulocyte Colony Stimulating Factor Adjuvant Role on the Immunological Response to Hepatitis B Vaccine in Patients With Cirrhosis: A Double Blind Randomized Placebo Controlled Trial

Kamran Bagheri Lankarani 1 , Mozaffar Talebzadeh 2 , Ahad Eshraghian 2 , * and Seyed Ali Malek-Hosseini 3
Authors Information
1 Health Policy Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran
2 Department of Internal Medicine, Shiraz University of Medical Sciences, Shiraz, IR Iran
3 Organ Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran
Article information
  • Hepatitis Monthly: May 01, 2014, 14 (5); e15447
  • Published Online: May 7, 2014
  • Article Type: Research Article
  • Received: October 16, 2013
  • Revised: December 31, 2013
  • Accepted: April 4, 2014
  • DOI: 10.5812/hepatmon.15447

To Cite: Bagheri Lankarani K, Talebzadeh M, Eshraghian A, Malek-Hosseini S A. Granulocyte Colony Stimulating Factor Adjuvant Role on the Immunological Response to Hepatitis B Vaccine in Patients With Cirrhosis: A Double Blind Randomized Placebo Controlled Trial, Hepat Mon. 2014 ; 14(5):e15447. doi: 10.5812/hepatmon.15447.

Copyright © 2014, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Starzl TE, Fung JJ. Themes of liver transplantation. Hepatology. 2010; 51(6): 1869-84[DOI][PubMed]
  • 2. Roche B, Samuel D, Gigou M, Feray C, Virot V, Schmets L, et al. De novo and apparent de novo hepatitis B virus infection after liver transplantation. Journal of Hepatology. 1997; 26(3): 517-26[DOI]
  • 3. Yu AS, Vierling JM, Colquhoun SD, Arnaout WS, Chan CK, Khanafshar E, et al. Transmission of hepatitis B infection from hepatitis B core antibody--positive liver allografts is prevented by lamivudine therapy. Liver Transpl. 2001; 7(6): 513-7[DOI][PubMed]
  • 4. Samuel D, Feray C, Bismuth H. Hepatitis viruses and liver transplantation. J Gastroenterol Hepatol. 1997; 12(9-10)-41[PubMed]
  • 5. Chalasani N, Smallwood G, Halcomb J, Fried MW, Boyer TD. Is vaccination against hepatitis B infection indicated in patients waiting for or after orthotopic liver transplantation? Liver Transpl Surg. 1998; 4(2): 128-32[PubMed]
  • 6. Villeneuve E, Vincelette J, Villeneuve JP. Ineffectiveness of hepatitis B vaccination in cirrhotic patients waiting for liver transplantation. Can J Gastroenterol. 2000; 14 Suppl B: 59B-62B[PubMed]
  • 7. Horlander JC, Boyle N, Manam R, Schenk M, Herring S, Kwo PY, et al. Vaccination against hepatitis B in patients with chronic liver disease awaiting liver transplantation. Am J Med Sci. 1999; 318(5): 304-7[PubMed]
  • 8. Arslan M, Wiesner RH, Sievers C, Egan K, Zein NN. Double-dose accelerated hepatitis B vaccine in patients with end-stage liver disease. Liver Transpl. 2001; 7(4): 314-20[DOI][PubMed]
  • 9. Carey W, Pimentel R, Westveer MK, Vogt D, Broughan T. Failure of hepatitis B immunization in liver transplant recipients: results of a prospective trial. Am J Gastroenterol. 1990; 85(12): 1590-2[PubMed]
  • 10. Kapoor D, Aggarwal SR, Singh NP, Thakur V, Sarin SK. Granulocyte-macrophage colony-stimulating factor enhances the efficacy of hepatitis B virus vaccine in previously unvaccinated haemodialysis patients. J Viral Hepat. 1999; 6(5): 405-9[PubMed]
  • 11. Pascasio JM, Aoufi S, Gash A, Sousa JM, Perea R, Sayago M, et al. Response to a vaccination schedule with 4 doses of 40 microg against hepatitis B virus in cirrhotic patients evaluated for liver transplantation. Transplant Proc. 2008; 40(9): 2943-5[DOI][PubMed]
  • 12. Bonazzi PR, Bacchella T, Freitas AC, Osaki KT, Lopes MH, Freire MP, et al. Double-dose hepatitis B vaccination in cirrhotic patients on a liver transplant waiting list. Braz J Infect Dis. 2008; 12(4): 306-9[PubMed]
  • 13. Klingemann HG. Clinical applications of recombinant human colony-stimulating factors. CMAJ. 1989; 140(2): 137-42[PubMed]
  • 14. Fabrizi F, Ganeshan SV, Dixit V, Martin P. Meta-analysis: the adjuvant role of granulocyte macrophage-colony stimulating factor on immunological response to hepatitis B virus vaccine in end-stage renal disease. Aliment Pharmacol Ther. 2006; 24(5): 789-96[DOI][PubMed]
  • 15. Ho P, Sherman P, Grigg A. Intermittent granulocyte colony-stimulating factor maintains dose intensity after ABVD therapy complicated by neutropenia. Eur J Haematol. 2012; 88(5): 416-21[DOI][PubMed]
  • 16. Deresinski SC. Granulocyte-macrophage colony-stimulating factor: potential therapeutic, immunological and antiretroviral effects in HIV infection. Aids. 1999; 13(6): 633-43[DOI]
  • 17. Arpinati M, Green CL, Heimfeld S, Heuser JE, Anasetti C. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood. 2000; 95(8): 2484-90[PubMed]
  • 18. Farag MM, Hoyler B, Encke J, Stremmel W, Weigand K. Dendritic cells can effectively be pulsed by HBVsvp and induce specific immune reactions in mice. Vaccine. 2010; 29(2): 200-6[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments